Chapuis Yves
Bull Acad Natl Med. 2013 Feb;197(2):515-21.
Absinthe (Artemisia absinthium) has been known for its medicinal properties since Antiquity. The Egyptians in 1600 BC, then Hippocrates, Galien, The Salerne School in 1649, and 18th-century physicians all recommended it for a variety of maladies. In 1780-1790 in Switzerland (Val de Travers), a traditional healer and, probably, a itinerant physician by the name of Docteur Ordinaire, transformed this purgative elixir into an aperitif liqueur, a move followed by two centuries of unexpected success. Absinthe was manufactured in France, at Pontarlier, for tax reasons. In 1900, the town counted 25 distilleries. Its production then extended to other French provinces. La fée verte ("green fairy") was particularly popular with the military, literary and artistic circles, and, finally the general public. In 1902, following a parliamentary vote, the Minister of the Interior asked the National Academy of Medicine to issue an opinion on "The indication of aperitif liqueurs, including absinthe". The Commission on Alcoholism, chaired by J.V. Laborde, examined the composition of absinthe liqueurs, the physiological and toxic action of their essences, the risks associated with "bitter" aperitifs, and the composition of essence-based liqueurs that were not used as aperitifs. The Commission compiled a list of the most dangerous aperitifs and liqueurs placing absinthe at the top, and recommended that the authorities prohibit the manufacture, circulation, advertisement and sale of all such drinks, including absinthe. However, because these drinks, and especially absinthe, represented an important source of tax revenue, this recommendation was only acted upon 13 years later, with a law adopted in March 1915. Despite subsequent prohibition of the production of absinthe liqueur, manufacturers in the Val de Travers region and a distillery in Pontarlier continued to work in secret until the prohibition was finally lifted in the year 2000. This decision was based on scientific analyses showing that thuyone was only toxic when ingested in very large amounts incompatible with normal consumption. In addition, it was found that the high alcohol content, often including adulterated alcohol, was particularly detrimental. A handful of manufacturers are now authorized, with strict limits placed on the alcohol content and thuyone concentration. Does this mean that the Academy of Medicine was wrong? While the report can be criticized, the fight against alcoholism was a worthy and necessary cause at the time, and remains so today.
苦艾酒(洋艾)自古便因其药用价值而闻名。公元前1600年的埃及人,以及后来的希波克拉底、盖伦、1649年的萨勒诺医学院和18世纪的医生们,都推荐用它来治疗各种疾病。1780年至1790年期间,在瑞士(特拉弗斯山谷),一位传统治疗师,或许还是一位名叫“Ordinaire医生”的巡回医生,将这种泻药制成了开胃利口酒,这一举措带来了两个世纪意想不到的成功。出于税收原因,苦艾酒在法国的蓬塔利耶生产。1900年,该镇有25家酿酒厂。其生产随后扩展到法国其他省份。“绿精灵”在军队、文学和艺术界尤其受欢迎,最终也受到了普通大众的喜爱。1902年,经过议会投票,内政部长要求国家医学科学院就“包括苦艾酒在内的开胃利口酒的适应症”发表意见。由J.V.拉博德主持的酒精中毒委员会,研究了苦艾利口酒的成分、其精华的生理和毒性作用、与“苦味”开胃酒相关的风险,以及不作为开胃酒使用的精华利口酒的成分。该委员会编制了一份最危险的开胃酒和利口酒清单,将苦艾酒列为榜首,并建议当局禁止生产、流通、广告和销售所有此类饮品,包括苦艾酒。然而,由于这些饮品,尤其是苦艾酒,是重要的税收来源,这一建议直到13年后,即1915年3月通过一项法律才得以实施。尽管随后禁止生产苦艾利口酒,但特拉弗斯山谷地区的制造商和蓬塔利耶的一家酿酒厂仍继续秘密生产,直到2000年禁令最终解除。这一决定基于科学分析,表明侧柏酮只有在摄入极大量与正常消费不相容的情况下才具有毒性。此外,还发现高酒精含量,通常还包括掺假酒精,特别有害。现在少数制造商被授权生产,但对酒精含量和侧柏酮浓度有严格限制。这是否意味着医学科学院错了呢?虽然该报告可能会受到批评,但当时反对酗酒是一项有价值且必要的事业,如今依然如此。